Jounce Therapeutics to Present at Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. JNCE, a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at three upcoming investor conferences:

• H.C. Wainwright 20^th Annual Global Investment Conference at 11:15 a.m. ET on Wednesday, September 5, 2018 in New York, NY
• Baird 2018 Global Healthcare Conference at 3:45 p.m. ET on Wednesday, September 5, 2018 in New York, NY
• 2018 Wells Fargo Healthcare Conference at 11:30 a.m. ET on Thursday, September 6, 2018 in Boston, MA

A live webcast of each presentation will be available by visiting "Events and Presentations" in the Investors and Media section of Jounce's website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following each presentation.

About Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce's lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently conducting the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com.

Investor Contact:

Komal Joshi

Jounce Therapeutics, Inc.

(857) 320-2523

kjoshi@jouncetx.com

Media Contact:

Gina Nugent

The Yates Network

(617) 460-3579

gina@theyatesnetwork.com